Provided by Tiger Trade Technology Pte. Ltd.

ALPHAMAB-B

8.450
+0.4004.97%
Volume:1.43M
Turnover:12.01M
Market Cap:8.17B
PE:-60.26
High:8.490
Open:8.100
Low:8.100
Close:8.050
52wk High:15.750
52wk Low:6.230
Shares:967.00M
HK Float Shares:967.00M
Volume Ratio:1.64
T/O Rate:0.15%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.140
ROE:-9.98%
ROA:-5.47%
PB:4.18
PE(LYR):-60.26
PS:13.50

Loading ...

BUZZ-Alphamab climbs most in over 8 weeks on progress of breast cancer treatment

Reuters
·
Jun 11

Alphamab-B Shares Surge on Positive Phase III Trial Results for Breast Cancer Treatment

Stock News
·
Jun 11

Alphamab Says Phase 3 Study of Breast Cancer Drug Meets Primary Endpoint

MT Newswires Live
·
Jun 11

Hong Kong Market Preview: US May CPI Rises 4.2% Year-on-Year; MIIT to Boost R&D for High-End Optoelectronic Chips

Stock News
·
Jun 11

BRIEF-Alphamab Oncology Says Phase III Clinical Study Of Anbenitamab Met Primary Endpoint

Reuters
·
Jun 10

Alphamab-B's Phase III Trial for KN026 in First-Line HER2-Positive Advanced Breast Cancer Hits Primary Endpoint

Stock News
·
Jun 10

Alphamab: Anbenitamab Phase III Trial Hits Primary Endpoint in First-Line HER2-Positive Advanced Breast Cancer

Bulletin Express
·
Jun 10

Alphamab Oncology says phase III trial of Anbenitamab plus albumin-bound docetaxel meets primary endpoint in first-line HER2+ advanced breast cancer

Reuters
·
Jun 10

Alphamab Oncology - Phase Iii Clinical Study of Anbenitamab (Kn026) as First-Line Treatment for Her2+ Advanced Breast Cancer Met Primary Endpoint

THOMSON REUTERS
·
Jun 10

HK Movers | Biotech Stocks Jump. Asymchem up Nearly 7%; SKB Bio up About 6%; Hengrui Pharma, Pharmaron, InnoGen up over 4%; Wuxi Apptec up 3%; Laekna, Joinn, Remegen up over 2%

Tiger Newspress
·
Jun 05

BRIEF-Alphamab Oncology Says CEO Buys 554,000 Shares On June 4

Reuters
·
Jun 05

ALPHAMAB-B Announces Share Purchases by Executive Director and Management

Deep News
·
Jun 05

Alphamab-B Executes Share Buyback, Spending HK$1.11 Million

Stock News
·
Jun 05

Alphamab Oncology: CEO Xu Ting Leads HK$4.99 Million Share Purchase; Post-Deal Stake Rises to 32.4%

Bulletin Express
·
Jun 05

Alphamab Oncology - CEO DR. Xu Ting Purchases 554,000 Shares on Open Market on June 4, 2026

THOMSON REUTERS
·
Jun 05

Alphamab Oncology - Aggregate Consideration for Share Purchases Totals HK$4.99 Mln at HK$7.375 per Share

THOMSON REUTERS
·
Jun 05

Alphamab Oncology Issues 88,000 New Shares in May; Total Issued Shares Reach 974.38 Million

Bulletin Express
·
Jun 04

Alphamab Oncology unveils favourable Phase I data for dual-target ADC JSKN016 in HER2- breast cancer at ASCO 2026

Bulletin Express
·
Jun 02

Alphamab Oncology presents Phase I ASCO data for JSKN016 in HER2-negative metastatic breast cancer

Reuters
·
Jun 02

BRIEF-Alphamab Oncology Says Phase III KN026-004 Study Enrolls 521 Patients And Meets Primary Endpoint

Reuters
·
Jun 01